Company intelligence / Profile preview

Protos Biotech

Jerusalem, Israel

Ownership: Private
Employees: ~10
Development stage: Other

Overview

ProtOS Bio is an AI-first protein design company focused on developing next-generation therapeutics for "undruggable" targets. The company leverages advanced AI foundation models to intentionally design therapeutic proteins and bespoke degraders with high specificity and efficiency. Backed by pioneers in the ubiquitin and targeted protein degradation (TPD) fields, including Nobel Laureate Aaron Ciechanover and Alessio Ciulli, ProtOS aims to address challenging unstructured targets and single nucleotide polymorphisms (SNPs) in oncology and neurodegeneration. The company operates in a discovery-stage partnership model to validate its platform and co-develop novel candidates.

Therapeutic areas: OncologyNeurology
Modalities: Targeted protein degradation therapySmall moleculeProteinAI-designed proteins
Industry: Biotech

Beyond the preview

Go deeper on Protos Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Protos Biotech.

Explore the full profile